News
RGLS
1.470
-3.92%
-0.060
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/17 21:31
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
Benzinga · 01/09 11:01
BRIEF-Regulus Therapeutics Inc - Sanofi Delivered Written Notice To Co To Terminate Second Amended, Restated Collaboration, License Agreement
Reuters · 01/06 21:27
Regulus Therapeutics Says Sanofi Delivered Written Notice To Co. To Terminate Second Amended, Restated Collaboration, License Agreement; Says In Accordance With Agreement, Termination Will Become Effective On Feb. 5, 2023
Benzinga · 01/06 21:12
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 12/09/2022 21:33
BRIEF-Regulus Therapeutics Reports Third Quarter 2022 Financial Results And Recent Updates
Reuters · 11/10/2022 21:22
Regulus Therapeutics GAAP EPS of -$0.50
Seekingalpha · 11/10/2022 21:20
Regulus Therapeutics Q3 EPS $(0.50) Misses $(0.49) Estimate
Benzinga · 11/10/2022 21:13
Notable earnings after Thursday's close
Seekingalpha · 11/09/2022 22:35
Earnings Outlook For Regulus Therapeutics
Benzinga · 11/09/2022 19:04
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/08/2022 12:11
Canaccord Genuity Initiates Coverage On Regulus Therapeutics with Buy Rating, Announces Price Target of $9
Benzinga · 11/08/2022 09:57
--Canaccord Genuity Starts Regulus Therapeutics at Buy With $9 Price Target
--Canaccord Genuity Starts Regulus Therapeutics at Buy With $9 Price Target
MT Newswires · 11/08/2022 08:49
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Benzinga · 11/03/2022 12:33
Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its third quarter 2022 financial re...
PR Newswire · 11/03/2022 12:00
BRIEF-Regulus Therapeutics Doses First Patient In Phase 1B Multiple-Ascending Dose Clinical Trial Of RGLS8429 For Treatment Of Autosomal Dominant Polycystic Kidney Disease
Reuters · 11/02/2022 12:50
Regulus Therapeutics Announces First Patient Dosed In Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Benzinga · 11/02/2022 12:01
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
Benzinga · 09/13/2022 09:14
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Benzinga · 09/12/2022 22:29
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 09/12/2022 17:57
More
Webull provides a variety of real-time RGLS stock news. You can receive the latest news about Regulus Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat diseases. The Company is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s product lead product candidates include RG-012 and RGLS8429. The Company is focused on evaluating a library of oligonucleotides designed to block miR-155 for the potential to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease). The Company also focuses on the evaluation of its designed compounds that inhibit miR-155 activity in microglia cell-based assays and in animal models of the disease, to identify potential candidates to advance into further studies. In addition to its focus on genetic kidney disease, the Company is focused on the research in technology to treat central nervous system (CNS) disease.